Dave Van Meter, president and CEO of Ivantis, updated OIS@ASCRS attendees on the Hydrus Microstent. Ivantis, like Glaukos, is focused on using the Schlemm’s canal as the point of outflow. “Our effort is to bring a more potent approach to Schlemm’s canal,” Van Meter says. The company is focused in the phaco/glaucoma market and stand-alone glaucoma market.
Ivantis anticipates releasing the full two-year results of its 558-patient HORIZON US pivotal trial. The company launched its new SUMMIT trial for refractory glaucoma. It expects to enroll its first patient in 30 days. Ivantis already is running its COMPARE trial in mild-to-moderate glaucoma. This makes the company the first to have two FDA pivotal trials on different stages of glaucoma.
The firm has raised $132 million and has treated over 3,200 patients.